Why Famotidine and Diphenhydramine Are Used Perioperatively
Famotidine for PONV
Famotidine is NOT a standard, evidence-based agent for postoperative nausea and vomiting (PONV) prophylaxis and should not be routinely used for this indication. The available evidence does not support H2-receptor antagonists as first-line antiemetics.
The Evidence Against Routine Use
The primary mechanism of famotidine is gastric acid suppression through H2-receptor blockade 1. While some older research suggested potential benefit—one Japanese study showed a trend toward reduced PONV in women receiving preoperative famotidine 2, and another study combining H1 and H2 blockers showed reduced PONV 3—these findings are not robust enough to justify routine use.
Current ERAS guidelines for colorectal and abdominal surgery make no mention of H2-blockers for PONV prophylaxis 4, 5. Instead, they recommend:
- First-line agents: 5-HT3 antagonists (ondansetron), dopamine antagonists (droperidol), and dexamethasone
- Risk-stratified approach: 2 drugs for patients with 1-2 risk factors; 2-3 drugs for patients with ≥2 risk factors 4, 5
- Each first-line agent provides approximately 25% relative risk reduction when used individually 4
When Famotidine IS Appropriate
Famotidine's legitimate perioperative role is aspiration prophylaxis—reducing gastric acidity in high-risk patients (emergency surgery, full stomach, severe GERD, gastroparesis). This is distinct from PONV prevention.
Diphenhydramine Before Anesthesia
Diphenhydramine is used as an adjunct sedative and for multimodal PONV prophylaxis, though its role has become increasingly limited and is NOT recommended as a single-agent antiemetic.
Legitimate Uses
1. Adjunct Sedation
Diphenhydramine (25-50 mg IV) has documented sedative properties that can enhance procedural sedation 6. In a randomized trial of 270 colonoscopy patients, diphenhydramine improved sedation scores and reduced requirements for meperidine (89.7 vs 100 mg) and midazolam (3.4 vs 4.0 mg) 6.
Key mechanism: H1-receptor antagonism with anticholinergic effects producing CNS depression. It has a modest stimulatory effect on ventilation and may counteract opioid-induced hypoventilation 6.
2. PONV Prophylaxis (Limited Role)
Recent research shows diphenhydramine can reduce PONV when combined with other antiemetics:
- In laparoscopic sleeve gastrectomy, diphenhydramine 0.4 mg/kg with acetaminophen and ondansetron reduced PONV from 56% to 30% in recovery 7
- In pediatric laparoscopic surgery, diphenhydramine reduced POV from 56.7% to 6.7% 8
- In high-risk pediatric adenotonsillectomy patients, adding diphenhydramine to standard prophylaxis significantly reduced PONV (p<0.0001) 9
Critical Limitations
The 2017 ASCO antiemetic guidelines explicitly removed diphenhydramine as an adjunctive antiemetic 10. The rationale: diphenhydramine was historically used to prevent extrapyramidal side effects from high-dose metoclopramide—a practice now obsolete with modern 5-HT3 antagonists.
Common pitfalls to avoid:
- Sedation: Prolongs recovery time, particularly problematic in elderly patients 8
- Anticholinergic effects: Dry mouth, blurred vision, urinary retention, confusion 6
- Not a first-line agent: Should never be used as monotherapy for PONV 10
- Impairs neurological assessment: Avoid in neurosurgical cases where serial exams are critical 11
The Modern Approach
For PONV prophylaxis, use evidence-based first-line agents 4:
- Ondansetron (5-HT3 antagonist)
- Dexamethasone 4-8 mg (single dose at induction)
- Droperidol (dopamine antagonist)
For anxiolysis/sedation, consider alternatives:
- Melatonin (equally effective to midazolam with fewer side effects) 4
- Avoid benzodiazepines in elderly patients (Beers Criteria) 4
If diphenhydramine is used, limit to:
- Adjunct sedation in difficult-to-sedate patients (chronic substance users) 6
- Third-line PONV prophylaxis in very high-risk patients already receiving 2-3 first-line agents
- Dose: 25-50 mg IV, recognizing increased sedation risk